射频消融联合索拉非尼和干扰素治疗复发性肝癌的临床研究  

Clinical Study on Radiofrequency Ablation,Sorafenib and Interferon-α for Recurrent Hepatocellular Carcinoma after Curative Resection

作　　者：肖华 许若才 刘寒春 李建良 余志渊 欧阳永忠 邱晓昕[1,3] 李清龙[4] 李永国[4] 朱海珍[5] 谢文彪[3] 谢海龙[3] 单汉国[3] 刘景诗 左朝晖 

机构地区：[1]湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院胃十二指肠胰腺外科湖南省肿瘤医院(湖南省肿瘤防治研究所)消化道肿瘤实验室,长沙410013 [2]湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院肝胆胰内科,长沙410013 [3]南华大学附属二医院普通外科肿瘤研究所,湖南衡阳410001 [4]中南大学湘雅二医院普通外科,长沙410011 [5]湖南大学生物学院分子医学系化学生物传感与计量学国家重点实验室,长沙410082

出　　处：《中国现代手术学杂志》2015年第5期338-342,共5页Chinese Journal of Modern Operative Surgery

基　　金：长沙市2014年度第三批科技计划项目(编号:k1403380-31)

摘　　要：目的探讨射频消融（radiofrequency Ablation,RFA）联合索拉非尼和干扰素治疗复发性肝癌的安全性和疗效。方法回顾性分析2006年1月-2013年12月期间69例行RFA联合索拉非尼治疗复发性肝癌患者的临床病例资料,根据是否使用干扰素分为干扰素组（n=34例）和对照组（n=35例）。比较两组患者治疗期间并发症的发生率,1、3和5年无瘤生存率和总体生存率等。结果两组患者的临床病理资料比较无统计学差异。与对照组相比,干扰素组治疗期间的并发症的发生率无明显增加（17.6%比17.1%,P=0.96）。干扰素组1、3和5年无瘤生存率分别为56.5%、21.2%和7.6%,而对照组分别为41.7%、22.7%和5.3%,组间比较差异无统计学意义（P=0.99）。干扰素组1、3和5年总体生存率分别为87.9%、45.1%和12.0%,而对照组分别为84.3%、27.4%和6.8%,组间比较差异具有统计学意义（P=0.04）。结论对于复发性肝癌患者,RFA联合索拉非尼和干扰素治疗复发性肝癌是安全、有效的,虽然不能延长患者无瘤生存率,但可提高患者的生活质量,延长患者的总体生存率。Objective To investigate the clinical effects and safety of radiofrequency ablation（ RFA）,sorafenib and interferon-α（ IFN-α） for patients with recurrent hepatocellular carcinoma（ HCC） after curative resection. Methods The clinical data of 69 cases diagnosed with recurrent HBV-related HCC and underwent curative resection between January 2006 and December 2013 were analyzed retrospectively. The 69 patients were divided into IFN group（ n = 34） and controlled group（ n = 35） for treating recurrent HCC according to carry out IFN-α therapy or not. The complication rates,1-,3-and 5-year disease-free survival and overall survival rates were evaluated and compared between two groups. Results The clinicopathological parameters and adverse effects were similar between the two groups（ P〉0. 05）. Compared with the controlled group,the complication rate of IFN group had not statistic difference（ 17. 6% vs. 17. 1%,P = 0. 96）. The 1-,3-and 5-year disease-free survival rates were 56. 5%,21. 2% and 7. 6% in the IFN group respectively,and were 41. 7%,22. 7% and 5. 3% in the controlled group respectively,there was no statistic difference between two groups（ P = 0. 99）. Whereas the 1-,3- and 5-year overall survival rates were 87. 9%,45. 1%and 12. 0% respectively in the IFN group,those were better than 84. 3%,27. 4% and 6. 8% respectively in the controlled group（ P = 0. 04）. Conclusion The treatment of RFA therapy,sorafenib and IFN-α is safe and effective for recurrent HCC after curative resection,and it can improve the overall survival in patients with HBV-related HCC.

关 键 词：癌 肝细胞 肿瘤复发 局部 射频消融 索拉非尼 干扰素-Α 

分 类 号：R735.7[医药卫生—肿瘤]